KALC 2026

Satellite Symposium I (A) - DAIICHI SANKYO KOREA
Satellite Symposium I (A) - DAIICHI SANKYO KOREA		ROOM A
Date & Time	September 10 (Thu), 2026, 08:20-09:00
Chair(s)	TBD
Speaker	08:30-09:10 Optimizing Treatment Strategies in HER2-Altered NSCLC Ja Hyun Yeo (Yonsei Cancer Center, Korea)

Session I (A).
Session I (A). Challenges in Diagnostic Pathology		ROOM A
Date & Time	September 10 (Thu), 2026, 09:20-10:20
Chair(s)	Sunhee Chang (Inje Univ., Korea), Mari Mino-Kenudson (Massachusetts General Hospital, USA)
Speaker	09:20-09:35 3D Approach of STAS Jeonghyo Lee (Seoul National Univ., Korea) 09:35-09:50 Staging in Multifocal LUAD Teh-Ying Chou (Shin Kong Wu Ho-Su Memorial Hospital, Taiwan) 09:50-10:05 LUSC Grading Mari Mino-Kenudson (Massachusetts General Hospital, USA) 10:05-10:20 Genomically Defined Tumors of the Lung Hee Sang Hwang (Univ. of Ulsan, Korea)

Session II (A).
Session II (A). Risk Factors & Prediction for Lung Cancer		ROOM A
Date & Time	September 10 (Thu), 2026, 10:35-11:35
Chair(s)	Sei-Hoon Yang (Wonkwang Univ., Korea), Melinda Aldrich (Vanderbilt Univ., USA)
Speaker	10:35-10:50 Global Trends in Lung Cancer Epidemiology Mattias Johansson (International Agency for Research on Lung Cancer, WHO, Sweden) 10:50-11:05 Environmental and Genetic Interplay in Various Populations Melinda Aldrich (Vanderbilt Univ., USA) 11:05-11:20 Lung Cancer in Never-Smokers: An Asian Perspective Jeong Uk Lim (The Catholic Univ. of Korea, Korea) 11:20-11:35 AI-Powered Risk Stratification and Prediction Models Edwin Ostrin (MD Anderson Cancer Center, USA)

Plenary Session
Plenary Session		ROOM A+B+C
Date & Time	September 10 (Thu), 2026, 11:50-12:30
Chair(s)	Myung-Ju Ahn (Hanyang Univ., Korea)
Speaker	11:50-12:30 Emerging Biology and Novel Targeting Strategies for Small Cell Lung Cancer Triparna Sen (Ohio State Univ., USA)

Luncheon Symposium I.
Luncheon Symposium I.		ROOM A+B+C
Date & Time	September 10 (Thu), 2026, 12:30-13:10
Chair(s)	Hyun Koo Kim (Korea Univ., Korea)
Speaker	12:30-13:10 KEYNOTE-671 Beyond Stage III: Expanding Perioperative Immunotherapy to Stage II NSCLC Jay Moon Lee (UCLA Health, USA)

Session III (A).
Session III (A). Surgery: MIS and Precision		ROOM A
Date & Time	September 10 (Thu), 2026, 13:30-14:30
Chair(s)	Suk Ki Cho (Seoul National Univ., Korea), Jessica Scott Donington (Univ. of Chicago, USA)
Speaker	13:30-13:45 Optimization of Robotic-Assisted Thoracic Surgery (RATS) Bernard Park (Memorial Sloan Kettering Cancer Center, USA) 13:45-14:00 Surgical Margins and Local Recurrence in Sublobar Resection Yasuhiro Tsutani (Kindai Univ., Japan) 14:00-14:15 MIS for Centrally Located Lung Cancer: Technical Tips Junghee Lee (Sungkyunkwan Univ., Korea) 14:15-14:30 Segmentectomy vs. Lobectomy: Lessons from Phase III Trials Jessica Scott Donington (Univ. of Chicago, USA)

Session IV (A).
Session IV (A). KALC-IC Spotlight: Featured Oral Abstracts I		ROOM A
Date & Time	September 10 (Thu), 2026, 14:45-15:45
Chair(s)	Sung Yong Lee (Korea Univ., Korea), Yeon Joo Jeong (Pusan National Univ., Korea)
Speaker	14:45-14:55 Lung Cancer Screening in Korean Women Who Have Never Smoked with a Family History of Lung Cancer: The NIKE Study So Yeon (lydia) Kim (Samsung Medical Center, Korea) 14:55-15:05 Beyond Solid Size: Favorable Prognostic Value of Ground-Glass Opacity in Stage IA Lung Adenocarcinoma Sung Goo Park (Samsung Medical Center, Korea) 15:05-15:15 Cardio-Oncology Clinic Involvement and Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Receiving Targeted Therapy Hyukjin Park (Chonnam National Univ., Korea) 15:15-15:25 Real-World Outcomes of Neoadjuvant Immunotherapy versus Definitive Chemoradiotherapy with Durvalumab Consolidation in Stage III Non-Small Cell Lung Cancer Hye In Lee (Seoul National Univ., Korea) 15:25-15:35 Interim Analysis of Camrelizumab Plus Pemetrexed and Carboplatin in Advanced Non-Squamous NSCLC Juwhan Choi (Korea Univ., Korea) 15:35-15:45 Autologous Vax-NK Consolidation Therapy in ES-SCLC: Identification of Predictive Biomarkers via High-Dimensional Circulating Immune Cell Profiling Sung-Woo Lee (Chonnam National Univ., Korea)

Satellite Symposium II (A) - YUHAN. Co
Satellite Symposium II (A) - YUHAN. Co		ROOM A
Date & Time	September 10 (Thu), 2026, 16:00-16:40
Chair(s)	TBD
Speaker	16:00-16:40 Lowering Hurdles, Improving Outcomes: Managing AE for Lazertinib-Based Regimens Tae-hwan Kim (Ajou Univ., Korea)

Satellite Symposium I (B) - Amgen
Satellite Symposium I (B) - Amgen		ROOM B
Date & Time	September 10 (Thu), 2026, 08:20-09:00
Chair(s)	TBD
Speaker	08:30-09:10 A Game Changer in SCLC Treatment: IMDELLTRA in 2L treatment Yaewon Yang (Chungbuk National Univ., Korea)

Session I (B).
Session I (B). Global Challenges and Optimal Strategies for Lung Cancer Screening		ROOM B+C
Date & Time	September 10 (Thu), 2026, 09:20-10:20
Chair(s)	Yeol Kim (National Cancer Center, Korea), Ricardo Sales dos Santos (ProPulmão Institute, Brazil)
Speaker	09:20-09:35 Implementing LDCT Screening in Resource-Limited Settings Ricardo Sales dos Santos (ProPulmão Institute, Brazil) 09:35-09:50 International Comparison of Lung Cancer Screening Protocols Kwun Fong (Univ. of Queensland, Australia) 09:50-10:05 Biomarkers and AI-driven Tools to Optimize Workflows and Interdisciplinary Collaboration Allison Chang (Harvard Medical School, USA) 10:05-10:20 Structured Reporting of Incidental Findings in Lung Cancer Screening: The Korean Experience Hyungjin Kim (Seoul National Univ., Korea)

Session II (B).
Session II (B). MDD 1: Oligometastatic Disease Management		ROOM B+C
Date & Time	September 10 (Thu), 2026, 10:35-11:35
Chair(s)	Hong-Gyun Wu (Seoul National Univ., Korea), Valerie W. Rusch (Memorial Sloan Kettering Cancer Center, USA)
Speaker	10:35-10:50 The Role of Surgery in Oligometastatic Lung Cancer Valerie W. Rusch (Memorial Sloan Kettering Cancer Center, USA) 10:50-11:05 SABR for Oligometastatic and Oligoprogressive Disease Florence Katie Keane (Mass General Brigham Cancer Institute, USA) 11:05-11:20 Integrating Systemic Therapy with Local Consolidation Helena Yu (Memorial Sloan Kettering Cancer Center, USA) 11:20-11:35 Radiological Assessment of Response to Local Therapies Sally Ayesa (Univ. of Sydney, Australia)

Session III (B).
Session III (B). Legacy of the Masters I: Shifting Paradigms in Thoracic Oncology		ROOM B+C
Date & Time	September 10 (Thu), 2026, 13:30-14:30
Chair(s)	Kye Young Lee (Konkuk Univ., Korea)
Speaker	13:30-13:50 20 Years of Pathology: From Histology to Precision Biomarkers Fred R. Hirsch (Mount Sinai, USA) 13:50-14:10 Development and Future of Molecular Targeted Therapy in Non-Small Cell Lung Cancer David R. Gandara (Univ. of California, USA) 14:10-14:30 20 Years of Innovation in Thoracic Surgery Hisao Asamura (Keio Univ., Japan)

Session IV (B).
Session IV (B). MDD 2: Multidisciplinary Mesothelioma Management		ROOM B+C
Date & Time	September 10 (Thu), 2026, 14:45-15:45
Chair(s)	Seung Hun Jang (Hallym Univ., Korea), Isabelle Schmitt-Opitz (Univ. Hospital Zurich, Switzerland)
Speaker	14:45-15:00 Diagnostic Dilemmas in Mesothelioma: Diving into the Differential Sonja Klebe (Flinders Univ., Australia) 15:00-15:15 Surgical Debulking: Pleurectomy/Decortication vs. EPP Isabelle Schmitt-Opitz (Univ. Hospital Zurich, Switzerland) 15:15-15:30 Updates on the 9th Edition IASLC Mesothelioma Staging Ritu R. Gill (Columbia Univ., USA) 15:30-15:45 Evolving Systemic Therapies for Mesothelioma Joachim Aerts (Erasmus MC, Netherlands)

Satellite Symposium II (B) - Johnson & Johnson Innovative Medicine
Satellite Symposium II (B) - Johnson & Johnson Innovative Medicine		ROOM B
Date & Time	September 10 (Thu), 2026, 16:00-16:40
Chair(s)	TBD
Speaker	16:00-16:40 Exon20ins: New Mechanisms, New Evidence, New Practice with Rybrevant Jung Seop Eom (Pusan National Univ., Korea)

Satellite Symposium I (C) - BORYUNG
Satellite Symposium I (C) - BORYUNG		ROOM C
Date & Time	September 10 (Thu), 2026, 08:20-09:00
Chair(s)	TBD
Speaker	08:30-09:10 Redefining First-Line Maintenance in ES-SCLC: Clinical Implications of the IMforte Regimen in Korean Practice Jang Ho Cho (Gachon Univ., Korea)

Satellite Symposium II (C) - BMS / ONO pharma Korea
Satellite Symposium II (C) - BMS / ONO pharma Korea		ROOM C
Date & Time	September 10 (Thu), 2026, 16:00-16:40
Chair(s)	TBD
Speaker	16:00-16:40 Expanding Treatment Possibilities: Nivolumab Across the Full Perioperative Spectrum in Resectable NSCLC with CM-77T Sun Min Lim (Yonsei Univ., Korea)

기획위원회 세션: 지역 완결형 폐암 진료 활성화 전략 (KOR)
기획위원회 세션: 지역 완결형 폐암 진료 활성화 전략 (KOR)		ROOM D
Date & Time	September 10 (Thu), 2026, 13:30-15:30
Chair(s)	류정선 (인하의대), 박인규 (서울의대)
Speaker	13:30-13:50 폐암 진료의 수도권 쏠림 실태와 원인 안준홍 (영남의대) 13:50-14:10 지역 폐암 센터 운영 전략과 실제: 충북대병원의 경험 김도훈 (충북의대) 14:10-14:30 지역 암센터 경쟁력 강화 모델: 화순전남대병원의 경험 김용협 (전남의대) 14:30-14:50 지역완결적 암관리를 위한 권역암센터 기능 재정립과 혁신 한규태 부장 (국립암센터) 14:50-15:10 지역 환자와의 신뢰 형성 전략 안효영 (부산의대) 15:10-15:30 패널토의 - 지역 치료 선택을 높이기 위한 실질적 대안과 정책 제언

Satellite Symposium III (A) - Roche Korea., co.ltd
Satellite Symposium III (A) - Roche Korea., co.ltd		ROOM A
Date & Time	September 11 (Fri), 2026, 08:20-09:00
Chair(s)	TBD
Speaker	08:20-09:00 Stepping Closer to Cure: New Horizon in Early NSCLC Treatment Powered by IMpower010 Seoyoung Lee (Yonsei Univ., Korea)

Session V (A).
Session V (A). KALC-IC Spotlight: Featured Oral Abstracts II		ROOM A
Date & Time	September 11 (Fri), 2026, 09:10-10:10
Chair(s)	Yoon Soo Chang (Yonsei Univ., Korea), Dong Hoon Shin (Pusan National Univ., Korea)
Speaker	09:10-09:20 Patient-Specific Lung Cancer Tumoroids for Studying Tumor-Stroma-Immune Interactions and Personalized Immuno-Oncology Yoo Ri Ko (Asan Medical Center, Korea) 09:20-09:30 Unbiased Transcriptome-Derived AI Classification of Tertiary Lymphoid Structures on H&E Images Predicts Survival and Immune Microenvironment in NSCLC Jaeyoon Lee (Northwestern Univ., Korea) 09:30-09:40 Prognostic Impact of Spread Through Air Spaces and Optimal Surgical Extent in Stage I NSCLC after Sublobar Resection Sangil Yun (Seoul National Univ., Korea) 09:40-09:50 Phenotype-Dependent Nonlinear Associations Between Tumor Size and Aggressive Histologic Features in Lung Adenocarcinoma Hyojin Kim (Seoul National Univ., Korea) 09:50-10:00 Beyond Major Pathological Response: Favorable Pathological Response Improves Risk Stratification After Neoadjuvant Chemoimmunotherapy for Resectable NSCLC Hsiang Teng (Tri-Service General Hospital, Taiwan) 10:00-10:10 Pathologic Response in Lymph Nodes after Neoadjuvant Therapy in NSCLC: Tumor Bed Extent, Not VT%, Drives Survival Associations Sungjin Kim (Seoul National Univ., Korea)

Session VI (A).
Session VI (A). The Molecular Narrative of Lung Cancer Evolution		ROOM A
Date & Time	September 11 (Fri), 2026, 10:25-11:25
Chair(s)	Wan-Seop Kim (Konkuk Univ., Korea), Sang-Won Um (Sungkyunkwan Univ., Korea)
Speaker	10:25-10:40 Combatting Acquired Resistance in Oncogene-Driven Lung Cancer: From Bench to Bedside Pasi A. Jänne (Dana-Farber Cancer Institute, USA) 10:40-10:55 Cancer-Associated Fibroblasts and Extracellular Matrix Remodeling in Lung Cancer Progression Young-Ho Ahn (Ewha Womans Univ., Korea) 10:55-11:10 Assessment of Lung Cancer Evolution by Liquid Biopsy Klaus Pantel (Univ. Medical Center Hamburg-Eppendorf, Germany) 11:10-11:25 Genomic–Transcriptomic Evolution in Lung Cancer and Metastasis Thomas Jones (Univ. College London, UK)

Luncheon Symposium II.
Luncheon Symposium II.		ROOM A+B+C
Date & Time	September 11 (Fri), 2026, 11:40-12:20
Chair(s)	Jae Cheol Lee (Univ. of Ulsan, Korea)
Speaker	11:40-12:20 A Decade of Transformation in EGFRm NSCLC: Redefining the Standard of Care with Tagrisso Pasi A. Jänne (Dana-Farber Cancer Institute, USA)

Session VII (A).
Session VII (A). Interventional Pulmonology Updates		ROOM A
Date & Time	September 11 (Fri), 2026, 12:50-13:50
Chair(s)	Changmin Choi (Univ. of Ulsan, Korea), Yun Chor Gary Lee (Univ. of Western Australia, Australia)
Speaker	12:50-13:05 Robotic Bronchoscopy for Peripheral Lung Cancer Pallav Shah (Royal Brompton Hospital, UK) 13:05-13:20 EBUS and Optimal Staging for Clinical N0-N1 NSCLC Anne Gonzalez (Mcgill Univ., Canada) 13:20-13:35 Therapeutic Bronchoscopy in Lung Cancer: Current and Emerging Roles Daniel Sterman (NYU Grossman School of Medicine, USA) 13:35-13:50 Medical Thoracoscopy: Contemporary Alternatives? Yun Chor Gary Lee (Univ. of Western Australia, Australia)

Session VIII (A).
Session VIII (A). SABR and Local Ablative Therapy		ROOM A
Date & Time	September 11 (Fri), 2026, 14:10-15:10
Chair(s)	Jin Hee Kim (Keimyung Univ., Korea), Shankar Siva (Peter MacCallum Cancer Centre, Australia)
Speaker	14:10-14:25 Recent Advances in SBRT for Early-Stage Lung Cancer Suresh Senan (Amsterdam Univ., Netherlands) 14:25-14:40 Synergistic Effects of SABR and Immunotherapy Shankar Siva (Peter MacCallum Cancer Centre, Australia) 14:40-14:55 Image-Guided Thermal Ablation: Current Status and Future Florian J. Fintelmann (Massachusetts General Hospital, USA) 14:55-15:10 Re-irradiation Strategies for Locoregional Recurrence Sue Sun Yom (Univ. of California San Francisco, USA)

Session IX (A).
Session IX (A). Supportive Care and Survivorship		ROOM A
Date & Time	September 11 (Fri), 2026, 15:20-16:20
Chair(s)	Jeong Eun Lee (Chungnam National Univ., Korea)
Speaker	15:20-15:40 Living Well with Cancer: Managing Life Beyond Diagnosis Nicole Kiss (Deakin Univ., Australia) 15:40-16:00 Managing Chronic Toxicities of Modern Therapies Margarita Majem (Hospital de la Santa Creu I Sant Pau, Spain) 16:00-16:20 From Survival to Survivorship: Patient-Centered Outcomes After Lung Cancer Surgery Hideo Ichimura (Univ. of Tsukuba, Japan)

Satellite Symposium III (B) - Pfizer Korea
Satellite Symposium III (B) - Pfizer Korea		ROOM B
Date & Time	September 11 (Fri), 2026, 08:20-09:00
Chair(s)	TBD
Speaker	08:20-09:00 CROWN 7Y: Elevating the Expectations for ALK+ mNSCLC with Lorlatinib Jii Bum (Joy) Lee (Yonsei Cancer Center, Korea)

Session V (B).
Session V (B). MDD 3: Diffuse Lung Disease & Operability		ROOM B+C
Date & Time	September 11 (Fri), 2026, 09:10-10:10
Chair(s)	Gong Yong Jin (Jeonbuk National Univ., Korea), Taewon Jang (Kosin Univ., Korea)
Speaker	09:10-09:25 Imaging Challenges in Lung Cancer Staging with ILD Kum Ju Chae (Jeonbuk National Univ., Korea) 09:25-09:40 Risk Assessment and Preoperative Optimization for ILD Patients Chi-Fu Jeffrey Yang (Massachusetts General Hospital, USA) 09:40-09:55 Postoperative Management and Prevention of Acute Exacerbation Hongseok Yoo (Sungkyunkwan Univ., Korea) 09:55-10:10 Pathological Perspective on Lung Cancer Arising in Interstitial Lung Disease Sehui Kim (Sungkyunkwan Univ., Korea)

Session VI (B).
Session VI (B). Next-Generation Immunotherapy and ADCs		ROOM B+C
Date & Time	September 11 (Fri), 2026, 10:25-11:25
Chair(s)	Se-Hoon Lee (Sungkyunkwan Univ., Korea), Scott Gettinger (Yale School of Medicine, USA)
Speaker	10:25-10:40 The Immunotherapy Revolution: From Early Studies to Standard of Care Scott Gettinger (Yale School of Medicine, USA) 10:40-10:55 Ivonescimab and the Future of Bispecific Antibodies Cathleen June Park (Memorial Sloan Kettering Cancer Center, USA) 10:55-11:10 Expanding the Arsenal: The Next Frontier of ADC Targets in Lung Cancer Susan Scott (Johns Hopkins Univ., USA) 11:10-11:25 Synergizing ADC and IO: A New Era to Delay Resistance Sun Min Lim (Yonsei Univ., Korea)

Session VII (B)
Session VII (B) Legacy of the Masters II: The Global Impact		ROOM B+C
Date & Time	September 11 (Fri), 2026, 12:50-13:50
Chair(s)	Young Chul Kim (Chonnam National Univ., Korea)
Speaker	12:50-13:10 The Evolution of Translational Research in Lung Cancer David P. Carbone (Ohio State Univ., USA) 13:10-13:30 Landmark Trials in SABR: From Early Stage to Oligometastasis Joe Y. Chang (MD Anderson Cancer Center, USA) 13:30-13:50 The Journey of Lung Cancer Therapy in Korea: Past, Present, and Future Keunchil Park (Sungkyunkwan Univ., Korea)

Session VIII (B).
Session VIII (B). MDD 4: Perioperative Treatment Strategies		ROOM B+C
Date & Time	September 11 (Fri), 2026, 14:10-15:10
Chair(s)	Jin Seok Ahn (Sungkyunkwan Univ., Korea), Deog Gon Cho (The Catholic Univ. of Korea, Korea)
Speaker	14:10-14:25 Neoadjuvant Immunotherapy: Changing the Surgical Paradigm Jonathan Spicer (Mcgill Univ., Canada) 14:25-14:40 Impact of Neoadjuvant Therapy on Surgical Complexity Kwon Joong Na (Seoul National Univ., Korea) 14:40-14:55 Pathological Complete Response (pCR) and ctDNA as Endpoints Kurt A. Schalper (Yale School of Medicine, USA) 14:55-15:10 Clinical Decision Making: Neoadjuvant vs. Adjuvant Approaches Jin-Hyoung Kang (The Catholic Univ. of Korea, Korea)

Session IX (B).
Session IX (B). Targeting DLL3 and the Next Wave of Precision Medicine in SCLC/LCNEC		ROOM B+C
Date & Time	September 11 (Fri), 2026, 15:20-16:20
Chair(s)	Hye Ryun Kim (Yonsei Univ., Korea), Anne-Marie Dingemans (Erasmus MC Cancer Institute, Rotterdam, Netherlands)
Speaker	15:20-15:35 Beyond DLL3: Navigating Novel Strategies and Global Perspectives in Advanced SCLC Kenneth O'Byrne (Princess Alexandra Hospital, Australia) 15:35-15:50 Evolutionary Trajectories of Small Cell Lung Cancer under Therapy Beung Chul Ahn (National Cancer Center, Korea) 15:50-16:05 Future Directions in Immunotherapy Combinations for SCLC Feng-Ming Kong (Univ. of Hong Kong, Hong Kong) 16:05-16:20 Unravelling the Molecular Spectrum of LCNEC: Implications for Treatment Selection Anne-Marie Dingemans (Erasmus MC Cancer Institute, Rotterdam, Netherlands)

Closing Symposium
Closing Symposium		ROOM B+C
Date & Time	September 11 (Fri), 2026, 16:20-17:00
Chair(s)	In-Jae Oh (Chonnam National Univ., Korea)
Speaker	16:20-17:00 Lazertinib as a New Standard for EGFRm+ NSCLC : Powerful as One, Stronger as Two Hyun Ae Jung (Sungkyunkwan Univ., Korea)

Satellite Symposium III (C) - BeOne Medicines Korea
Satellite Symposium III (C) - BeOne Medicines Korea		ROOM C
Date & Time	September 11 (Fri), 2026, 08:20-09:00
Chair(s)	TBD
Speaker	08:20-09:00 From Evidence to Practice: Integrating TEVIMBRA into Routine Clinical Practice Beung Chul Ahn (National Cancer Center, Korea)

폐암의날
폐암의날		ROOM D
Date & Time	September 11 (Fri), 2026, 13:30-15:30

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0215	PE1-01	Clinical Relevance of Pleural Tissue Debris Incidentally Obtained During Catheter Drainage for Pleural Effusion	Jiwon Kim	Kyung Hee University Medical Center	Korea
A-0189	PE1-02	A Radiomics-based Nomogram for Preoperative Prediction of Pathological Subtypes in Nodular Lung Adenocarcinoma: a Multicenter Study	Xiaocui Liu	Union Hospital, Tongji Medical College, Huazhong University Of Science And Technology	China
A-0161	PE1-03	Dual Modulation of Redox and Immune Signaling in Lung Cancer via Pharmacoinformatic Study of Benzothiazepine-Based Immunomodulators Targeting Nrf2 and JAK2-JH1	Rizki Rachmad Saputra	Universitas Palangka Raya	Indonesia
A-0131	PE1-04	Molecular Adaptation Reveals Metabolic and Stress Response Bypass Pathways in Erlotinib-Resistant Non-Small Cell Lung Cancer Subclones	Nadyatul Husna	Universitas Andalas/ Dr. Reksodiwiryo Military Hospital Padang	Indonesia
A-0118	PE1-05	Uncovering Multi-Layered Resistance Mechanisms to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer	Nadyatul Husna	Universitas Andalas/ Dr. Reksodiwiryo Military Hospital Padang	Indonesia
A-0093	PE1-06	Natural Triterpenoids of Peronema canescens as Dual Inhibitors of AKT1 and ERK1/2: A Structure-Based Approach for Overcoming Lung Cancer	Rizki Rachmad Saputra	Universitas Palangka Raya	Indonesia
A-0076	PE1-07	Development of a Novel Inhibitor Against nRAS-Mutated Lung Cancers.	Vikas Kumar	Aiims New Delhi	India
A-0059	PE1-08	Solid Lipid Nanoparticle of Ganodric acid ameliorate benzopyrene induced lung cancer in rats Via Alteration of Nrf2/HO-1 Signaling pathway	V Kumar	Shalom Institute Of Health & Allied Sciences	India
A-0236	PE1-09	Decoding the Role of myomiR-206 in Lung Cancer Cachexia and Its Correlation with IL-6 Signaling	Divo Helmizar	Stan / Perbendaharaan Negara	Indonesia
A-0233	PE1-10	Decoding Hematologic Paraneoplastic Syndromes in Lung Cancer: A Critical Approach to Early Diagnosis	Aryofri Afan	Andalas University	Indonesia
A-0220	PE1-11	Establishment of a Lung Organoid Library from Diverse Clinical Samples for Advanced Disease Modeling	Joo-Eun Lee	Chungnam National University Hospital	Korea
A-0208	PE1-12	Role of PFKFB3 in Maintaining Redox Homeostasis and DNA Integrity in Non-Small Cell Lung Cancer Cells Treated with EGFR-TKIs	Brijalkumar Patel	Gmers Medical College	India
A-0207	PE1-13	Follicular lymphoma presenting with solitary pulmonary nodule: two case reports	Heae Surng Park	Ewha Womans University Medical Center	Korea
A-0181	PE1-14	Nutritional and Lifestyle Interventions in Lung Cancer Prevention and Survivorship in Indonesia	Helen Try Juniasti	Cendrawasih University	Indonesia
A-0174	PE1-15	Enhancing Quality of Life in Lung Cancer Patients: Integrating Palliative Care with Immunotherapy and Targeted Therapy	Yesika Simbolon	Atmajaya University	Australia
A-0134	PE1-16	Genetic Analysis of Compositions For Diagnosing Lung Cancer Comprising Peptide Nucleic Acid Probe Complementary To Lung Cancer Related Mutations	Ramlah Ramlah	Universitas Sulawesi Barat esia	Indonesia
A-0100	PE1-17	Spread Through Air Spaces in EGFR-mutated Lung Adenocarcinomas: Prevalence and Prognostic Significance	Yeon Bi Han	Seoul National University Bundang Hospital	Korea
A-0095	PE1-18	Decoding Alternative Splicing-Driven Immune Escape in Rare Lung Adenocarcinoma Subtypes Using Deep Learning and Minor Spliceosome Signatures	Rini Winarti	Yogyakarta State University	Indonesia
A-0081	PE1-19	Integrated Multi-Omics Profiling Identifies CEBPA as an Aging-Related Prognostic Biomarker in NSCLC	Jiaqi Zhu	Affiliated Hospital Of Nantong University	China
A-0038	PE1-20	Investigating the Role and Mechanisms of USP18-Mediated YAP Deubiquitination in Radiation-Induced Lung Injury	Haochun Guo	Zhongda Hospital, Medical School Of Southeast University	China
A-0037	PE1-21	Exploring the protection effects of Taxifolin on alleviating radiation-induced lung injury basing on USP18	Haochun Guo	Zhongda Hospital, Medical School Of Southeast University	China
A-0035	PE1-22	Comprehensive Analysis of Matrisome-Related Genes Reveals Prognostic Value and Immune Landscape in Lung Cancer	Hou Wang	Ningbo No.2 Hospital	China

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0096	PE1-23	A Peritumor-based Model Combining 3D Deep Learning and Radiomics for Preoperatively Predicting STAS in Invasive Lung Adenocarcinoma: a Multicenter Study	Xiaocui Liu	Union Hospital, Tongji Medical College, Huazhong University Of Science And Technology	China
A-0244	PE1-24	Machine Learning Algorithms' Use in Plasma Biomarker-Based Lung Cancer Diagnosis	Siska Azizah	Baiturrahmah Universitya	Indonesia
A-0211	PE1-25	An AI-powered holotomography platform for predicting drug response in patient-derived lung cancer organoids	Mahn Jae Lee	Chungnam National University Hospital	Korea
A-0135	PE1-26	Development of Big Data for Predecting Lung Cancar (Study in Asia)	Rara Yulianda	Sulthan Thaha Saifuddin Islamic State University	Indonesia
A-0132	PE1-27	Enhancing using Artificial Intelligence in Detecting Lung Cancer in Asia	Rani Marsyanda	Sultan Thaha Saifuddin Islamic State University	Indonesia
A-0120	PE1-28	A Comprehensive Review of Legal and Ethical in the Implementation of AI & Big Data in Lung Cancer Diagnosis	Ferza Alfath	Alumnus Universitas Andalas	Indonesia
A-0119	PE1-29	AI-Driven Multi-Modal Prediction of Post-Surgical Recurrence in Brain-Metastatic Lung Adenocarcinoma: Integrating Tumor Dormancy, Stromal Remodeling, and TME Immune Exclusion Signals	Elfiany Syafruddin	Blk Muhammadiyah University	Indonesia
A-0075	PE1-30	Comparative Risk of Neurological Adverse Events Between PD-1 and PD-L1 Inhibitors in Korean Lung Cancer Patients: A Nationwide Cohort Study	Seung Hyeun Lee	Kyung Hee University Medical Center	Korea
A-0067	PE1-31	Applying machine learning (ML) and artificial intelligence (AI) techniques to predict the risk of lung cancer in region of Chhattisgarh.	Manvendra Singh	Hmfa Miet	India

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0170	PE1-32	Assessment of the association between expression of Cyclin D1 protein with the clinicopathological characteristics and prognosis of lung cancer	Usha J Satanee	Nanduba Medical Center	India
A-0127	PE1-33	Trends of positive rates of initial screening and repeated screening in national organized population-based lung cancer screening in Korea	Nayoung Lee	National Cancer Center	Korea
A-0217	PE1-34	Economic Burden and Cost-Effectiveness of Lung Cancer Management in Indonesia: Evidence from Smoking-Attributable Mortality and EGFR-Targeted Therapies	Pisi Bethania Titalessy	Universitas Cenderawasih	Indonesia
A-0117	PE1-35	Highly Sensitive Digital Profiling of Tumor-derived Extracellular Vesicle RNA for EML4-ALK Mutations in Non-small Cell Lung Cancer	Beomseok Lee	Labspinner, Inc.	Korea
A-0173	PE1-36	Impact Evaluation of Cigarette Excise and Pricing on Smoking Habits and Lung Cancer Disease in Indonesia	Lintong Hottua Simbolon	The Pranala Institute	Indonesia

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0240	PE1-37	ECMO as a Procedural Bridge for Malignant Airway Obstruction	Hyeong Jun Cho	The Catholic University of Korea Seoul St. Mary's Hospital	Korea
A-0230	PE1-38	Enhancing Early-Stage Lung Cancer Diagnosis: The Role of Bronchoscopic Biomarkers in Improving Accuracy and Personalizing Treatment	Roland Helmizar	Faculty Of Medicine, Baiturrahmah University	Indonesia
A-0121	PE1-39	Initial Experience of EBUS-TBNA in Mongolia: Diagnosing 13R Squamous Cell Carcinoma Without Radial Ultrasound	Davaajav Nyamluvsan	The First Central Hospital of Mongolia	Mongolia

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0232	PE1-40	Long-Term Projections of Tracheal, Bronchus, and Lung Cancer in Indonesia’s Productive-Age Population	Najwa Aisya Putri	International Open University	Indonesia
A-0225	PE1-41	Contrasting Mortality Patterns of Lung Cancer in Young Adults (25-29 Years) Across Global Socio-Demographic Contexts, 2015-2021	Najwa Aisya Putri	International Open University	Indonesia
A-0223	PE1-42	Divergent Global Trends in Lung Cancer Mortality Among Young Adults (25-29 Years) by Socio-Demographic Index: Projections to 2050	Najwa Aisya Putri	International Open University	Indonesia
A-0205	PE1-43	Mapping the Burden of Tracheal, Bronchus, and Lung Cancer: Age-Based and SDI-Level Comparisons from the GBD 2021	Nabila Zahra Athirah	Islamic University Of Indonesia	Indonesia
A-0204	PE1-44	Unveiling the Burden of Smoking on Lung Cancer in Indonesia: A Quantitative Assessment from 2017 to 2021	Najwa Aisya Putri	International Open University	Indonesia
A-0031	PE1-45	Indoor air pollution and risk of hypopharyngeal/laryngeal and lung cancers in New Delhi, India	Monirujjaman Biswas	Jawaharlal Nehru University	India
A-0030	PE1-46	Examining the differences between non-smokers and smokers of lung cancer: Insights from a Tertiary Centre in Delhi, India	Monirujjaman Biswas	Jawaharlal Nehru University	India
A-0020	PE1-47	Trends and Survival Outcomes of Lung Cancer Surgery in South Korea, 2015-2019	Chanwoo Kim	Chungbuk National University	Korea
A-0243	PE1-48	Regional Trends in Lung Cancer in Southeast Asia: Analysis of Mortality Proportion, Daily Life Expectancy (DALYs), and Prevalence	Derizal Derizal	Ip Trisakti	Indonesia
A-0239	PE1-49	Identification of Environmental, Behavioral, and Metabolic Risk Factors for Lung Cancer Mortality: A Statistical Approach	Putri Ayu	Andalas University	Indonesia
A-0201	PE1-50	Preventing Chronic Lung Disease Early: Evidence of the Impact of Parenting and Mental Health from the Indonesian Family Life Survey	Derizal Derizal	Ip Trisakti	Indonesia
A-0087	PE1-51	User Satisfaction and Reading Efficiency of an AI-Based Quality Control System in Korean National Lung Cancer Screening	Kang Jegu	National Cancer Center	Korea
A-0086	PE1-52	Urban-Rural Disparities in Lung Cancer Diagnosis and Treatment in Indonesia: A Nationwide Review	Rinita Istiqomah	Universitas Jambi	Indonesia
A-0074	PE1-53	Single Round LDCT Screening in Men Aged 70 Years: Prevalence of Pulmonary Nodules and Lung Cancer Detection	Hyerin Kang	Dongtan Sacred Heart Hospital	Korea
A-0056	PE1-54	Air Pollution and Lung Cancer in a Changing Climate Through Projected Risks and Molecular Impacts of PM2.5 Exposure	Firdian Makrufardi	Integrated Medical, Molecular, And Data Science Research Foundation	Indonesia
A-0027	PE1-55	Sex-Specific Associations of Total Bilirubin, ALBI, and PALBI with Lung Cancer Risk: Interactions with Smoking and Alcohol	Jong Won Shin	Asan Medical Center	Korea
A-0026	PE1-56	Risk and Incidence of Drug-Induced Interstitial Lung Disease Associated with Anti-Neoplastic Therapy: A Nationwide Population-Based Study in Korea	Seung Hyeun Lee	College of Medicine, Kyung Hee University, Kyung Hee University Hospital	Korea
A-0019	PE1-57	Association between Creatinine and Lung Cancer Risk in Men Smokers: A Comparative Analysis with Antioxidant Biomarkers from the KCPS-II Cohort	Jong Won Shin	Asan Medical Center	Korea

Scientific Program